Post-trial follow-up | Long-term outcomes of adjuvant denosumab in breast cancer.
22 Nov, 2022 | 13:14h | UTCLong-Term Outcomes of Adjuvant Denosumab in Breast Cancer – NEJM Evidence
Original Study: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)